Iovance Biotherapeutics, Inc. announced that Wendy Dixon, Ph.D. who has been a member of Board of Directors since 2022, will not stand for re-election at the Annual Meeting, to be held on June 6, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.1 USD | -3.23% | -16.49% | -0.37% |
06-01 | Transcript : Iovance Biotherapeutics, Inc. - Special Call | |
05-13 | Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.37% | 2.27B | |
-41.39% | 8.02B | |
+3.25% | 3.43B | |
-19.19% | 2.03B | |
-22.57% | 1.63B | |
+32.82% | 1.16B | |
-8.30% | 703M | |
+14.12% | 714M | |
-31.22% | 500M | |
-4.97% | 279M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics, Inc. Announces Wendy Dixon, Member of Board of Directors, Will Not Stand for Re-Election